NCT07361705 2026-01-23
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 1 Not yet recruiting
Clinical Trials
14 trialsNCT07098806 2025-08-01
CA2024-LM-001
Plus Therapeutics
Phase 1 Recruiting
NCT00527410 2025-05-30
LMD
Biogen
Phase 1 Terminated
NCT05034497 2025-03-26
ReSPECT-LM
Plus Therapeutics
Phase 1 Active not recruiting
NCT05146219 2024-12-30
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
TYK Medicines, Inc
Phase 2 Completed
NCT03275402 2024-02-13
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Y-mAbs Therapeutics
Phase 2/3 Terminated
NCT00089245 2023-12-26
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Y-mAbs Therapeutics
Phase 1 Terminated
NCT05414123 2023-10-16
FORESEE
Biocept, Inc.
Terminated
NCT03613181 2023-04-24
ANGLeD
Angiochem Inc
Phase 3 Unknown
NCT04315246 2022-07-15
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Y-mAbs Therapeutics
Phase 1/2 Withdrawn
NCT02616393 2022-03-16
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation, LLC
Phase 2 Completed
NCT02228369 2021-01-05
BLOOM
AstraZeneca
Phase 1 Completed
NCT02755987 2016-06-07
Expanded Access to ANG1005 for Individual Patients
Angiochem Inc
No longer available
NCT00854867 2014-02-24
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
Mundipharma Research Limited
Phase 1 Completed